21.40
-0.2(-0.93%)
Currency In USD
| Previous Close | 21.6 |
| Open | 21.25 |
| Day High | 22.17 |
| Day Low | 20.88 |
| 52-Week High | 45 |
| 52-Week Low | 7.65 |
| Volume | 73,977 |
| Average Volume | 95,488 |
| Market Cap | 454.62M |
| PE | -0.94 |
| EPS | -22.75 |
| Moving Average 50 Days | 27.57 |
| Moving Average 200 Days | 16.44 |
| Change | -0.2 |
If you invested $1000 in Lyell Immunopharma, Inc. (LYEL) since IPO date, it would be worth $63.35 as of February 21, 2026 at a share price of $21.4. Whereas If you bought $1000 worth of Lyell Immunopharma, Inc. (LYEL) shares 3 years ago, it would be worth $443.98 as of February 21, 2026 at a share price of $21.4.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma
GlobeNewswire Inc.
Feb 12, 2026 12:30 PM GMT
PiNACLE – H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving treatment in the second-line s
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
GlobeNewswire Inc.
Dec 07, 2025 9:30 PM GMT
93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting83% overall response and 61% complete response rates in cohort comprised predominantly of
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
GlobeNewswire Inc.
Nov 10, 2025 12:30 PM GMT
LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer enrolled in an ongoing U.S. Phase 1 c